ECT-001 (UM171) Expanded Cord Blood Transplant to Treat High-risk Multiple Myeloma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03441958|
Recruitment Status : Recruiting
First Posted : February 22, 2018
Last Update Posted : January 27, 2021
Multiple Myeloma (MM) is a morbid disease associated with a poor outcome and while current therapies with new drugs have improved survival, MM still remains incurable in most patients. The only potential curative treatment remains allogeneic Hematopoietic stem cell transplant (HSCT), as shown by our cohort of 92 newly diagnosed patients who received a sibling tandem auto-allo (HSCT) with an estimated 10-year progression free survival (PFS) of 43%. However, the high incidences of toxicities including chronic graft-versus-host-disease (GVHD) (up to 79%) and disease progression (up to 49%) impair improvement in cure rate. Using umbilical cord blood (CB) as an alternative source of hematopoietic stem cells (HSC) could be superior biologically because of their increased proliferative capacity, greater number of progeny with longer telomeres and better anti-tumor efficacy in presence of positive residual disease. Moreover, using CB has been shown to decrease incidence of chronic GVHD. However, CBs have the disadvantage of having a limited HSC dose leading to prolonged cytopenia and higher risk of infections.
In a first in-human trial using CB expanded with the ECT-001 (UM171) molecule (clinicaltrial.gov # NCT02668315), the median net expansion of HSC was 36 fold, which allows for the selection of better HLA matched CB regardless of their lower HSC dose. Moreover, the ECT-001 expanded CBs have a different cell composition than regular CBs, with more than 25% of dendritic cell precursors. This, combined to better HLA matched CBs, may reduce chronic GVHD incidence and improve immune reconstitution. To date, 22 patients received an ECT-001 expanded CB and the procedure proved to be safe and feasible.
In this new trial, the goal is to evaluate the safety and efficacy of ECT-001 expanded CB transplant in high risk MM patients.
|Condition or disease||Intervention/treatment||Phase|
|Multiple Myeloma||Biological: ECT-001 (UM171) expanded cord blood||Phase 1 Phase 2|
This is a single institution, prospective, phase I/II open-label study in a maximum of 20 patients evaluating a novel treatment strategy in NDMM patients with high-risk disease who do not have a 6/6 compatible sibling donor. Participating patients will be from Hôpital Maisonneuve-Rosemont (HMR) or referred to HMR for this protocol. Newly diagnosed multiple myeloma patients will be evaluated for eligibility before or during the autologous stem cell transplant (ASCT) period. After a Bortezomib-based induction treatment (VTD, CyBorD, RVD or PAD [in patients with plasma cell leukemia]) for a minimum of 4 cycles, followed by Melphalan ≥ 140 mg/m2 and ASCT, eligible patients who accept to participate will undergo screening evaluation to receive a Reduced Intensity (RIC) allogeneic HSCT with ECT-001 expanded CB. It is estimated that 18 months will be necessary to enroll the targeted sample size.
Once eligibility has been confirmed, study treatment will begin. After an ASCT, eligible patients will receive a conditioning regimen before receiving a RIC allogeneic HSCT with an ECT-001 expanded CB on day 0. Patients will be followed at least every week for the first 3 months, then every month, in the absence of GVHD, for disease evaluation and adverse events. Occurrence and severity of acute GVHD will be evaluated using the modified Glucksberg176 and IBMTR177 criteria, while chronic GVHD will be evaluated using the NIH178 criteria.
The trial will be terminated when all patients have been followed for 5 years after allogeneic HSCT.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase I-II Open-label Study of Reduced Intensity-allogeneic Transplant of ECT-001 (UM171/ Fed-batch Culture System) Expanded Cord Blood in Patients With High-risk Multiple Myeloma|
|Actual Study Start Date :||March 7, 2018|
|Estimated Primary Completion Date :||March 1, 2022|
|Estimated Study Completion Date :||March 1, 2024|
Experimental: ECT-001 (UM171) expanded cord blood
Biological: ECT-001 (UM171) expanded cord blood
ECT-001 expanded cord-blood will be produced and infused on site
- Safety of ECT-001 expanded CB expansion as measured by toxicity evaluation [ Time Frame: 5 years ]AEs with a CTCAE grade ≥ 3 (non hematologic) and with a grade ≥ 4 (hematologic) will be reported from the beginning of the conditioning regimen up to 5 years after CB transplant.
- Feasibility of ECT-001 expanded CB expansion [ Time Frame: 5 years ]Number of successful expansion and infusions in an outpatient nonmyeloablative transplant condition for high-risk myeloma patients
- Measure of the kinetics of donor lymphoid cells recovery [ Time Frame: 2 years ]Donor lymphocytes cells recovery assessed by chimerism analysis.
- Measure of the kinetics of donor myeloid cells recovery [ Time Frame: 2 years ]Time to neutrophils and platelets engraftment will be measured
- Incidence of chronic GVHD by grade at 1 years by NIH criteria. [ Time Frame: 1 year ]The incidence of chronic GVHD will be evaluated at 1 years using the recommendations of the NIH Consensus Conference and recently updated. Analysis by cumulative incidence
- Incidence of chronic GVHD by grade at 2 years by NIH criteria. [ Time Frame: 2 years ]The incidence of chronic GVHD will be evaluated at 1 years using the recommendations of the NIH Consensus Conference and recently updated. Analysis by cumulative incidence
- Correlation between neutrophil and CD34+ doses infused [ Time Frame: 2 years ]Regression analysis
- Correlation between neutrophil and CD34+CD45RA+ doses infused [ Time Frame: 2 years ]Regression analysis. Time to neutrophil and platelet engraftment will be correlated to the CD34+ and the CD34+CD45RA- dose (which includes all human hematopoietic stem cells (HSCs): long term and short term repopulating cells) contained in the expanded graft. Expansion and cultures might change the characteristics and behaviour of CD34+ cells, hence the need to look at the correlation between primitive CD34+CD45RA- subpopulation and engraftment.
- Incidence of graft failure [ Time Frame: 2 years ]Cumulative incidence of graft failure by type (primary or secondary). For Primary engraftment failure will be defined as non-achieving a T lymphocyte chimerism of ≥30% at D+28 and ≥70% at D+180. Secondary graft failure will be defined as followed : ANC drops below 0.5x109/L for 14 consecutive days, unresponsive to G-CSF without any identifiable cause (medication, viral infection, vitamin deficiency or other) or <5% donor chimerism at any time point beyond initial engraftment in the absence of relapse and graft dominance by 2nd infused cord or other stem cell source.
- Evaluation of T Cells reconstitution [ Time Frame: 3 years ]
Evaluation at several levels :
- Multiparametric flow cytometry to quantify the proportion of naïve (CD45RA+/CD27+) and memory (CD45RA-/CD27+) cells.
- TREC to measure thymic output
- Diversity of the T cell repertoire (deep sequencing)
- T-cell function (Elispot assays)
- Evaluation of B cells reconstitution [ Time Frame: 3 years ]B cell evaluation will be carried out prospectively using flow cytometry (CD19+), immunoglobulin (Ig) measurements, and PCR for donor B cell chimerism .
- Evaluation of NK Cells reconstitution [ Time Frame: 3 years ]NK cell evaluation will be performed by flow cytometry (CD 16+/56+) and chimerism analysis.
- Evaluation of expanded HSC activity in vivo [ Time Frame: 3 years ]Standard in vitro (long term culture-initiating cells and colony forming cells) and in vivo (the NSG mouse model) assays
- Incidence of acute GVHD at day +120 [ Time Frame: 4 months ]Analysis by cumulative incidence
- Incidence of acute GVHD at 6 month [ Time Frame: 6 months ]Analysis by cumulative incidence
- Incidence of acute GVHD at 1 year [ Time Frame: 1 year ]Analysis by cumulative incidence
- Incidence of grade >=3 infectious complications [ Time Frame: 5 years ]Analysis by cumulative incidence
- Incidence of engraftment syndrome requiring therapy [ Time Frame: 2 years ]Analysis by cumulative incidence
- Duration of hospitalization [ Time Frame: 6 months ]Number of days of hospitalization during the first 180 days post-transplant
- Non relapse mortality at day +120 [ Time Frame: 4 months ]Analysis by cumulative incidence
- Non relapse mortality at 1 year [ Time Frame: 1 year ]Analysis by cumulative incidence
- Non relapse mortality at 2 year [ Time Frame: 2 years ]Analysis by cumulative incidence
- Progression free survival at 2 years [ Time Frame: 2 years ]Kaplan Meier analysis
- Overall survival at 2 years [ Time Frame: 2 years ]Kaplan Meier analysis
- Response to treatment at 1 year after allogeneic transplant [ Time Frame: 1 years ]Evaluation of response categories according to the International Myeloma Working Group (IMWG)
- Response to treatment at 2 year after allogeneic transplant [ Time Frame: 2 years ]Evaluation of response categories according to the International Myeloma Working Group (IMWG)
- Best response achieve at 1 year after allogeneic transplant [ Time Frame: 1 years ]Evaluation of the best response during the 1 st year post-transplant
- Best response achieve at 2 year after allogeneic transplant [ Time Frame: 2 years ]Evaluation of the best response during the 2 years post-transplant
- Minimal residual disease post transplant [ Time Frame: 5 years ]Next Generation flow cytometry to determine how efficient an expanded CB is at reducing MM burden
- Patient's quality of life [ Time Frame: 5 years ]Assessment through Quality of Life questionnaires
- Pharmaco-economic evaluation of the proposed treatment [ Time Frame: 5 years ]Developement of an analysis model to determine if ECT-001 expanded CB to treat MM has a better cost-efficiency ratio than conventional chemotherapy-based treatment
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03441958
|Contact: Jean Roy, MDfirstname.lastname@example.org|
|Contact: Hocine Ait Hamouda, MSc||514-252-3400 ext email@example.com|
|CIUSSS de l'Est-de-l'île-de-Montréal, Installation Hôpital Maisonneuve Rosemond||Recruiting|
|Montréal, Quebec, Canada, H1T2M4|
|Contact: Séverine Landais, PhD 514-252-3400 ext 3609 firstname.lastname@example.org|
|Contact: Jean Roy, MD 514-252-3400 email@example.com|
|Principal Investigator:||Jean Roy, MD||Ciusss de L'Est de l'Île de Montréal|